Clinical Neuropathology practice guide 5-2015: MGMT methylation pyrosequencing in glioblastoma: unresolved issues and open questions

Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma

Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807 · see citing works

The 2007 WHO Classification of Tumours of the Central Nervous System

Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., Scheithauer, B. W., & Kleihues, P. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0243-4 · Cited by 15,422 · see citing works

Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial

Malmström, A., Grønberg, B. H., Marosi, C., Stupp, R., Frappaz, D., Schultz, H., Abacıoğlu, U., Tavelin, B., Lhermitte, B., Hegi, M. E., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70265-6 · Cited by 1,282 · see citing works

Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia.

Esteller, M., Hamilton, S. R., Burger, P. C., Baylin, S. B., & Herman, J. G. (1999) · PubMed · Cited by 1,253 · see citing works

Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial

Wick, W., Platten, M., Meisner, C., Felsberg, J., Tabatabai, G., Simon, M., Nikkhah, G., Papsdorf, K., Steinbach, J. P., Sabel, M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70164-x · Cited by 1,136 · see citing works

EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma

Weller, M., van den Bent, M. J., Hopkins, K., Tonn, J. C., Stupp, R., Falini, A., Moyal, E. C., Frappaz, D., Henriksson, R., Balañá, C., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70011-7 · Cited by 754 · see citing works

Clinical Trial Designs for Predictive Marker Validation in Cancer Treatment Trials

Sargent, D. J., Conley, B. A., Allegra, C. J., & Collette, L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.112 · Cited by 500 · see citing works

Clinical Trial Designs for Predictive Biomarker Validation: Theoretical Considerations and Practical Challenges

Mandrekar, S. J., & Sargent, D. J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.3701 · Cited by 404 · see citing works

MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status

Bady, P., Sciuscio, D., Diserens, A., Bloch, J., van den Bent, M. J., Marosi, C., Dietrich, P.-Y., Weller, M., Mariani, L., Heppner, F. L., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-1016-2 · Cited by 345 · see citing works

Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy

Dunn, J. R., Baborie, A., Alam, F., Joyce, K. A., Moxham, M., Sibson, R., Crooks, D. A., Husband, D. J., Shenoy, A., Brodbelt, A. R., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605127 · Cited by 322 · see citing works

The 2016 World Health Organization classification of tumours of the central nervous system

Villa, C., Miquel, C., Mosses, D., Bernier, M., & Stefano, A. L. D. (2018) · La Presse Médicale · doi:10.1016/j.lpm.2018.04.015 · Cited by 319 · see citing works

Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas

Felsberg, J., Thon, N., Eigenbrod, S., Hentschel, B., Sabel, M., Westphal, M., Schackert, G., Kreth, F. W., Pietsch, T., Löffler, M., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.26083 · Cited by 298 · see citing works

Predictive impact of MGMT promoter methylation in glioblastoma of the elderly

Reifenberger, G., Hentschel, B., Felsberg, J., Schackert, G., Simon, M., Schnell, O., Westphal, M., Wick, W., Pietsch, T., Loeffler, M., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.27385 · Cited by 256 · see citing works

Biomarker-Adaptive Threshold Design: A Procedure for Evaluating Treatment With Possible Biomarker-Defined Subset Effect

Jiang, W., Freidlin, B., & Simon, R. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm022 · Cited by 253 · see citing works

Optimization of Quantitative MGMT Promoter Methylation Analysis Using Pyrosequencing and Combined Bisulfite Restriction Analysis

Mikeska, T., Bock, C., El‐Maarri, O., Hübner, A., Ehrentraut, D., Schramm, J., Felsberg, J., Kahl, P., Büttner, R., Pietsch, T., et al. (2007) · Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2007.060167 · Cited by 241 · see citing works

Comparative assessment of 5 methods (methylation‐specific polymerase chain reaction, methylight, pyrosequencing, methylation‐sensitive high‐resolution melting, and immunohistochemistry) to analyze O6‐methylguanine‐DNA‐methyltranferase in a series of 100 glioblastoma patients

Quillien, V., Lavenu, A., Karayan, L., Carpentier, C., Labussière, M., Lesimple, T., Chinot, O. L., Wager, M., Honnorat, J., Saïkali, S., et al. (2012) · Cancer · doi:10.1002/cncr.27392 · Cited by 213 · see citing works

Prognostic value of O6-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods

Karayan, L., Quillien, V., Guilhot, J., Wager, M., Fromont, G., Saïkali, S., Etcheverry, A., Hamlat, A., Loussouarn, D., Campion, L., et al. (2009) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-0031-1 · Cited by 187 · see citing works

Biomarker enrichment strategies: matching trial design to biomarker credentials

Freidlin, B., & Korn, E. L. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.218 · Cited by 178 · see citing works

Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas

Everhard, S., Tost, J., abdalaoui, H. E., Crinière, E., Busato, F., Marie, Y., Gut, I. G., Sanson, M., Mokhtari, K., Laigle–Donadey, F., et al. (2009) · Neuro-Oncology · doi:10.1215/15228517-2009-001 · Cited by 177 · see citing works

A distinct region of the MGMT CpG island critical for transcriptional regulation is preferentially methylated in glioblastoma cells and xenografts

Malley, D. S., Hamoudi, R., Kocialkowski, S., Pearson, D. M., Collins, V. P., & Ichimura, K. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0803-5 · Cited by 152 · see citing works

Prognostic Value of Three Different Methods of MGMT Promoter Methylation Analysis in a Prospective Trial on Newly Diagnosed Glioblastoma

Christians, A., Hartmann, C. J., Benner, A., Meyer, J., von Deimling, A., Weller, M., Wick, W., & Weiler, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033449 · Cited by 146 · see citing works

Characterization of the promoter region of the human O6-methylguanine-DNA methyltransferase gene

Harris, L. C., Potter, P. M., Tano, K., Shiota, S., MITRA, S. P., & Brent, T. P. (1991) · Nucleic Acids Research · doi:10.1093/nar/19.22.6163 · Cited by 139 · see citing works

Correlation of IDH1 Mutation with Clinicopathologic Factors and Prognosis in Primary Glioblastoma: A Report of 118 Patients from China

Yan, W., Zhang, W., You, G., Bao, Z., Wang, Y., Liu, Y., Kang, C., You, Y., Wang, L., & Jiang, T. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030339 · Cited by 135 · see citing works

The Global DNA Methylation Surrogate LINE-1 Methylation Is Correlated with MGMT Promoter Methylation and Is a Better Prognostic Factor for Glioma

Ohka, F., Natsume, A., Motomura, K., Kishida, Y., Kondo, Y., Abé, T., Nakasu, Y., Namba, H., Wakai, K., Fukui, T., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023332 · Cited by 116 · see citing works

MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR

Håvik, A. B., Brandal, P., Honne, H., Dahlback, H. S., Scheie, D., Hektoen, M., Meling, T. R., Helseth, E., Heim, S., Lothe, R. A., et al. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-36 · Cited by 114 · see citing works

Clinical Trial Designs for Predictive Biomarker Validation: One Size Does Not Fit All

Mandrekar, S. J., & Sargent, D. J. (2009) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543400902802458 · Cited by 113 · see citing works

Correlation of MGMT promoter methylation status with gene and protein expression levels in glioblastoma

Uno, M., Oba‐Shinjo, S. M., Camargo, A. A., de Moura, R. P., de Aguiar, P. H. P., Cabrera, H. N., Begnami, M. F. S., Rosemberg, S., Teixeira, M. J., & Marie, S. K. N. (2011) · Clinics · doi:10.1590/s1807-59322011001000013 · Cited by 109 · see citing works

Predictive biomarker validation in practice: lessons from real trials

Mandrekar, S. J., & Sargent, D. J. (2010) · Clinical Trials · doi:10.1177/1740774510368574 · Cited by 92 · see citing works

Study Designs and Statistical Analyses for Biomarker Research

Gosho, M., Nagashima, K., & Sato, Y. (2012) · Sensors · doi:10.3390/s120708966 · Cited by 81 · see citing works

MGMT CpG island is invariably methylated in adult astrocytic and oligodendroglial tumors with IDH1 or IDH2 mutations

Mulholland, S. A., Pearson, D. M., Hamoudi, R., Malley, D. S., Smith, C. M., Weaver, J. M. J., Jones, D., Kocialkowski, S., Bäcklund, L. M., Collins, V. P., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.26499 · Cited by 81 · see citing works

Outcome-based determination of optimal pyrosequencing assay for MGMT methylation detection in glioblastoma patients

Quillien, V., Lavenu, A., Sanson, M., Legrain, M., Dubus, P. R., Karayan, L., Mosser, J., Ichimura, K., & Figarella-Branger, D. F. (2014) · Journal of Neuro-Oncology · doi:10.1007/s11060-013-1332-y · Cited by 74 · see citing works

Identification of a 6-Cytokine Prognostic Signature in Patients with Primary Glioblastoma Harboring M2 Microglia/Macrophage Phenotype Relevance

Cai, J., Zhang, W., Yang, P., Wang, Y., Li, M., Zhang, C., Wang, Z., Hu, H., Liu, Y., Li, Q., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0126022 · Cited by 73 · see citing works

TheMGMTpromoter SNP rs16906252 is a risk factor forMGMTmethylation in glioblastoma and is predictive of response to temozolomide

Rapkins, R. W., Wang, F., Nguyen, H. N., Cloughesy, T. F., Lai, A., Ha, W., Nowak, A. K., Hitchins, M. P., & McDonald, K. L. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov064 · Cited by 67 · see citing works

Continuous low-dose temozolomide and celecoxib in recurrent glioblastoma

Stockhammer, F., Misch, M., Koch, A., Czabanka, M., Plotkin, M., Blechschmidt, C., Tuettenberg, J., & Vajkoczy, P. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0192-y · Cited by 56 · see citing works

The T genotype of the MGMT C>T (rs16906252) enhancer single-nucleotide polymorphism (SNP) is associated with promoter methylation and longer survival in glioblastoma patients

McDonald, K. L., Rapkins, R. W., Olivier, J., Zhao, L., Nozue, K., Lu, D., Tiwari, S., Kuroiwa‐Trzmielina, J., Brewer, J. M., Wheeler, H., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.08.012 · Cited by 55 · see citing works

Clinical Neuropathology practice news 1-2014: Pyrosequencing meets clinical and analytical performance criteria for routine testing of MGMT promoter methylation status in glioblastoma

Preusser, M., Berghoff, A. S., Manzl, C., Filipits, M., Weinhäusel, A., Pulverer, W., Dieckmann, K. U., Widhalm, G., Wöehrer, A., Knosp, E., et al. (2013) · Clinical Neuropathology · doi:10.5414/np300730 · Cited by 54 · see citing works

Epigenetic modulation of the drug resistance genes MGMT, ABCB1 and ABCG2 in glioblastoma multiforme

Oberstadt, M. C., Bien-Möller, S., Weitmann, K., Herzog, S., Hentschel, K., Rimmbach, C., Vogelgesang, S., Balz, E., Fink, M. A., Michael, H., et al. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-617 · Cited by 48 · see citing works

Identification of a 59 bp enhancer located at the first exon/intron boundary of the human O6-methylguanine DNA methyltransferease gene

Harris, L. C., Remack, J. S., & Brent, T. P. (1994) · Nucleic Acids Research · doi:10.1093/nar/22.22.4614 · Cited by 43 · see citing works

Detection of MGMT promoter methylation in glioblastoma using pyrosequencing.

Xie, H., Tubbs, R., & Yang, B. (2015) · PubMed · Cited by 40 · see citing works

What Constitutes Reasonable Evidence of Efficacy and Effectiveness to Guide Oncology Treatment Decisions?

Sargent, D. J. (2010) · The Oncologist · doi:10.1634/theoncologist.2010-s1-19 · Cited by 36 · see citing works

MGMT Promoter Methylation Correlates with an Overall Survival Benefit in Chinese High-Grade Glioblastoma Patients Treated with Radiotherapy and Alkylating Agent-Based Chemotherapy: A Single-Institution Study

Shen, D., Liu, T., Lin, Q., Lu, X., Wang, Q., Lin, F., & Mao, W. (2014) · PLoS ONE · doi:10.1371/journal.pone.0107558 · Cited by 32 · see citing works

Prognostic and predictive markers in recurrent high grade glioma; results from the BR12 randomised trial

Collins, V. P., Ichimura, K., Di, Y., Pearson, D. M., Chan, R., Thompson, L. C., Gabe, R., Brada, M., & Stenning, S. P. (2014) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-2-68 · Cited by 32 · see citing works

Biomarkers, subgroup evaluation, and clinical trial design.

Baker, S. G., Kramer, B. S., Sargent, D. J., & Bonetti, M. (2012) · PubMed · Cited by 30 · see citing works

Prognosis of glioblastoma with faint MGMT methylation-specific PCR product

Hsu, C., Ho, H., Lin, S., Chang‐Chien, Y., Chen, M.-H., Hsu, S. P. C., Yen, Y., Guo, W.-Y., & Ho, D. M. (2015) · Journal of Neuro-Oncology · doi:10.1007/s11060-014-1701-1 · Cited by 27 · see citing works

MGMT Promoter Methylation and Glioblastoma: A Comparison of Analytical Methods and of Tumor Specimens

Lattanzio, L., Borgognone, M., Mocellini, C., Giordano, F., Favata, E., Fasano, G., Vivenza, D., Monteverde, M., Tonissi, F., Ghiglia, A., et al. (2015) · The International Journal of Biological Markers · doi:10.5301/jbm.5000126 · Cited by 24 · see citing works

Incorporation of Biomarker Assessment in Novel Clinical Trial Designs: Personalizing Brain Tumor Treatments

Galanis, E., Wu, W., Sarkaria, J. N., Chang, S. M., Colman, H., Sargent, D. J., & Reardon, D. A. (2010) · Current Oncology Reports · doi:10.1007/s11912-010-0144-x · Cited by 24 · see citing works

Clinical neuropathology practice guide 06-2012: MGMT testing in elderly glioblastoma patients yes, but how?

Berghoff, A. S., & Preusser, M. (2012) · Clinical Neuropathology · doi:10.5414/np300576 · Cited by 20 · see citing works

Correlation between quantified promoter methylation and enzymatic activity of O 6-methylguanine-DNA methyltransferase in glioblastomas

Kishida, Y., Natsume, A., Toda, H., Toi, Y., Motomura, K., Koyama, H., Matsuda, K., Nakayama, O., Sato, M., Suzuki, M., et al. (2012) · Tumor Biology · doi:10.1007/s13277-012-0319-1 · Cited by 18 · see citing works

The hypermethylation of the O6‐methylguanine‐DNA methyltransferase gene promoter in gliomas—correlation with array comparative genome hybridization results and IDH1 mutation

Tuononen, K., Tynninen, O., Sarhadi, V. K., Tyybäkinoja, A., Lindlöf, M., Antikainen, M. S. H., Näpänkangas, J. P., Hirvonen, A., Mäenpää, H. O., Paetau, A. E., et al. (2011) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20927 · Cited by 15 · see citing works

Identifying cut points for biomarker defined subset effects in clinical trials with survival endpoints

He, P. (2014) · Contemporary Clinical Trials · doi:10.1016/j.cct.2014.06.005 · Cited by 6 · see citing works

Analysis of DNA methylation in cancer: location revisited

Koch, A., Joosten, S. C., Feng, Z., de Ruijter, T. C., Draht, M. X., Melotte, V., Smits, K. M., Veeck, J., Herman, J. G., Van Neste, L., et al. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0004-4 · Cited by 710 · see citing works

The roles of DNA, RNA and histone methylation in ageing and cancer

Michalak, E. M., Burr, M. L., Bannister, A. J., & Dawson, M. A. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0143-1 · Cited by 549 · see citing works

MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges

Mansouri, A., Hachem, L. D., Mansouri, S., Nassiri, F., Laperrière, N., Xia, D., Lindeman, N. I., Wen, P. Y., Chakravarti, A., Mehta, M. P., et al. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy132 · Cited by 343 · see citing works

The DNA methylation landscape of glioblastoma disease progression shows extensive heterogeneity in time and space

Klughammer, J., Kiesel, B., Roetzer-Pejrimovsky, T., Fortelny, N., Nemc, A., Nenning, K., Furtner, J., Sheffield, N. C., Datlinger, P., Peter, N., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0156-x · Cited by 326 · see citing works

Intratumor DNA methylation heterogeneity in glioblastoma: implications for DNA methylation-based classification

Wenger, A., Vega, S. F., Kling, T., Bontell, T. O., Jakola, A. S., & Carén, H. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz011 · Cited by 136 · see citing works

Glioblastoma vs temozolomide: can the red queen race be won?

Arora, A., & Somasundaram, K. (2019) · Cancer Biology & Therapy · doi:10.1080/15384047.2019.1599662 · Cited by 131 · see citing works

Predictive MGMT status in a homogeneous cohort of IDH wildtype glioblastoma patients

Radke, J., Koch, A., Pritsch, F., Schumann, E., Misch, M., Hempt, C., Lenz, K., Loebel, F., Paschereit, F., Heppner, F. L., et al. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0745-z · Cited by 81 · see citing works

Radiotherapy in Glioblastoma: the Past, the Present and the Future

Gzell, C., Back, M., Wheeler, H., Bailey, D. L., & Foote, M. C. (2016) · Clinical Oncology · doi:10.1016/j.clon.2016.09.015 · Cited by 78 · see citing works

Validation of the high-performance of pyrosequencing for clinical MGMT testing on a cohort of glioblastoma patients from a prospective dedicated multicentric trial

Quillien, V., Lavenu, A., Ducray, F., Joly, M., Chinot, O. L., Fina, F., Sanson, M., Carpentier, C., Karayan, L., Rivet, P., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11322 · Cited by 61 · see citing works

MGMT Gene Promoter Methylation Status – Assessment of Two Pyrosequencing Kits and Three Methylation-specific PCR Methods for their Predictive Capacity in Glioblastomas

Johannessen, L. E., Brandal, P., Myklebust, T. Å., Heim, S., Micci, F., & Panagopoulos, I. (2018) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20102 · Cited by 54 · see citing works

Genome‐wide association and multi‐omics studies identify MGMT as a novel risk gene for Alzheimer's disease among women

Chung, J., Das, A., Sun, X., Sobreira, D. R., Leung, Y. Y., Igartua, C., Mozaffari, S. V., Chou, Y., Thiagalingam, S., Mez, J. B., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12719 · Cited by 52 · see citing works

Prognostic value of test(s) for O6-methylguanine–DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide

McAleenan, A., Kelly, C., Spiga, F., Kernohan, A., Cheng, H., Dawson, S., Schmidt, L., Robinson, T., Brandner, S., Faulkner, C., et al. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013316.pub2 · Cited by 49 · see citing works

PITX2 DNA Methylation as Biomarker for Individualized Risk Assessment of Prostate Cancer in Core Biopsies

Uhl, B., Gevensleben, H., Tolkach, Y., Sailer, V., Majores, M., Jung, M., Meller, S., Stein, J., Ellinger, J., Dietrich, D., et al. (2016) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2016.08.008 · Cited by 47 · see citing works

Defining optimal cutoff value of MGMT promoter methylation by ROC analysis for clinical setting in glioblastoma patients

Yuan, G., Niu, L., Zhang, Y., Wang, X., Ma, K., Yin, H., Dai, J., Zhou, W., & Pan, Y. (2017) · Journal of Neuro-Oncology · doi:10.1007/s11060-017-2433-9 · Cited by 46 · see citing works

A novel analytical model of MGMT methylation pyrosequencing offers improved predictive performance in patients with gliomas

Chai, R., Liu, Y., Zhang, K., Wu, F., Zhao, Z., Wang, K., Jiang, T., & Wang, Y. (2018) · Modern Pathology · doi:10.1038/s41379-018-0143-2 · Cited by 44 · see citing works

A novel Cas9-targeted long-read assay for simultaneous detection of IDH1/2 mutations and clinically relevant MGMT methylation in fresh biopsies of diffuse glioma

Wongsurawat, T., Jenjaroenpun, P., Loose, A. D., Alkam, D., Ussery, D. W., Nookaew, I., Leung, Y., Ho, S., Day, J. D., & Rodriguez, A. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-00963-0 · Cited by 42 · see citing works

Incorporating Advances in Molecular Pathology Into Brain Tumor Diagnostics

Vega, J. E. V., & Brat, D. J. (2018) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000186 · Cited by 40 · see citing works

Pyrosequencing versus methylation-specific PCR for assessment of MGMT methylation in tumor and blood samples of glioblastoma patients

Estival, A., Sanz, C., Ramírez, J. L., Velarde, J. M., Doménech, M., Carrato, C., Peñas, R. D. L., Gil‐Gil, M., Sepúlveda-Sánchez, J. M., García‐Armengol, R., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-47642-2 · Cited by 40 · see citing works

Randomized phase III trial of metabolic imaging-guided dose escalation of radio-chemotherapy in patients with newly diagnosed glioblastoma (SPECTRO GLIO trial)

Laprie, A., Noël, G., Chaltiel, L., Truc, G., Sunyach, M., Charissoux, M., Magné, N., Auberdiac, P., Biau, J., Ken, S., et al. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noad119 · Cited by 39 · see citing works

Combinations of four or more CpGs methylation present equivalent predictive value for MGMT expression and temozolomide therapeutic prognosis in gliomas

Chai, R., Zhang, K., Liu, Y., Wu, F., Zhao, Z., Wang, K., Jiang, T., & Wang, Y. (2018) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13040 · Cited by 36 · see citing works

Challenges and Perspectives of Standard Therapy and Drug Development in High-Grade Gliomas

Chelliah, S. S., Paul, E. A. L., Kamarudin, M. N. A., & Parhar, I. S. (2021) · Molecules · doi:10.3390/molecules26041169 · Cited by 32 · see citing works

Prognostic Relevance of Tumor Purity and Interaction with MGMT Methylation in Glioblastoma

Heuling, E. S., Knab, F., Radke, J., Eskilsson, E., Martínez-Ledesma, E., Koch, A., Czabanka, M., Dieterich, C., Verhaak, R. G. W., Harms, C., et al. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0322 · Cited by 31 · see citing works

A prospective study on neurocognitive effects after primary radiotherapy in high-grade glioma patients

Bodensohn, R., Corradini, S., Ganswindt, U., Hofmaier, J., Schnell, O., Belka, C., & Niyazi, M. (2015) · International Journal of Clinical Oncology · doi:10.1007/s10147-015-0941-1 · Cited by 29 · see citing works

Extent of MGMT promoter methylation modifies the effect of temozolomide on overall survival in patients with glioblastoma: a regional cohort study

Poon, M. T. C., Keni, S., Vimalan, V., Ip, C. L., Smith, C., Erridge, S., Weir, C. J., & Brennan, P. M. (2021) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdab171 · Cited by 27 · see citing works

MGMT Testing in Glioblastomas

Philteos, J., Karmur, B. S., & Mansouri, A. (2018) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000490 · Cited by 25 · see citing works

PITX2andPANCRDNA methylation predicts overall survival in patients with head and neck squamous cell carcinoma

Sailer, V. W., Holmes, E. E., Gevensleben, H., Goltz, D., Dröge, F., de Vos, L., Franzen, A., Schröck, F., Bootz, F., Kristiansen, G., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12417 · Cited by 24 · see citing works

Identifying the optimal cutoff point for MGMT promoter methylation status in glioblastoma

Nguyen, N. T. K., Redfield, J. L., Ballo, M. T., Michael, M., Sorenson, J., Dibaba, D. T., Wan, J. Y., Ramos, G. M. D., & Pandey, M. K. (2021) · CNS Oncology · doi:10.2217/cns-2021-0002 · Cited by 23 · see citing works

Association between MGMT Enhancer Methylation and MGMT Promoter Methylation, MGMT Protein Expression, and Overall Survival in Glioblastoma

Zappe, K., Pühringer, K., Pflug, S., Berger, D., Böhm, A., Spiegl‐Kreinecker, S., & Cichna‐Markl, M. (2023) · Cells · doi:10.3390/cells12121639 · Cited by 22 · see citing works

Definition of the Prognostic Role of MGMT Promoter Methylation Value by Pyrosequencing in Newly Diagnosed IDH Wild-Type Glioblastoma Patients Treated with Radiochemotherapy: A Large Multicenter Study

Caccese, M., Simonelli, M., Villani, V., Rizzato, S., Ius, T., Pasqualetti, F., Russo, M., Rudà, R., Amoroso, R., Bellu, L., et al. (2022) · Cancers · doi:10.3390/cancers14102425 · Cited by 21 · see citing works

Clinical validation of the CE-IVD marked Therascreen MGMT kit in a cohort of glioblastoma patients

Quillien, V., Lavenu, A., Ducray, F., Meyronet, D., Chinot, O. L., Fina, F., Sanson, M., Carpentier, C., Karayan, L., Rivet, P., et al. (2017) · Cancer Biomarkers · doi:10.3233/cbm-170191 · Cited by 21 · see citing works

Clinical validation of a novel quantitative assay for the detection of MGMT methylation in glioblastoma patients

Rosas-Alonso, R., Colmenarejo-Fernández, J., Pernía, O., Rodríguez‐Antolín, C., Esteban, I., Ghanem, I., Sánchez-Cabrero, D., Losantos-García, I., Palacios-Zambrano, S., Moreno‐Bueno, G., et al. (2021) · Clinical Epigenetics · doi:10.1186/s13148-021-01044-2 · Cited by 20 · see citing works

The number of methylated CpG sites within the MGMT promoter region linearly correlates with outcome in glioblastoma receiving alkylating agents

Siller, S., Lauseker, M., Karschnia, P., Niyazi, M., Eigenbrod, S., Giese, A., & Tonn, J. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01134-5 · Cited by 19 · see citing works

MGMT-Methylation in Non-Neoplastic Diseases of the Central Nervous System

Teuber‐Hanselmann, S., Worm, K., Macha, N., & Junker, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22083845 · Cited by 18 · see citing works

MGMT Methylation and Differential Survival Impact by Sex in Glioblastoma

Barnett, A. E., Ozair, A., Bamashmos, A. S., Li, H., Bosler, D. S., Yeaney, G. A., Ali, A., Peereboom, D. M., Lathia, J. D., & Ahluwalia, M. S. (2024) · Cancers · doi:10.3390/cancers16071374 · Cited by 15 · see citing works

High density DNA methylation array is a reliable alternative for PCR-based analysis of the MGMT promoter methylation status in glioblastoma

Braczynski, A. K., Capper, D., Jones, D., Schittenhelm, J., Stichel, D., von Deimling, A., Harter, P. N., & Mittelbronn, M. G. A. (2019) · Pathology - Research and Practice · doi:10.1016/j.prp.2019.152728 · Cited by 13 · see citing works

Pyrosequencing Analysis ofMGMTPromoter Methylation in Meningioma

Panagopoulos, I., Gorunova, L., Leske, H., Niehusmann, P., Johannessen, L. E., Staurseth, J., ØINO, N., Meling, T. R., Heim, S., Micci, F., et al. (2018) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20096 · Cited by 12 · see citing works

Pyrosequencing Analysis of O-6-Methylguanine-DNA Methyltransferase Methylation at Different Cut-Offs of Positivity Associated with Treatment Response and Disease-Specific Survival in Isocitrate Dehydrogenase-Wildtype Grade 4 Glioblastoma

Silva, F. F. V. E., Domenico, M. D., Caponio, V. C. A., Pérez‐Sayáns, M., Camolesi, G. C. V., Rojo-Álvarez, L. I., Ballini, A., Garcı́a, A. G., Padín-Iruegas, E., & Peñaranda, J. M. S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25010612 · Cited by 8 · see citing works

Glioblastoma in the real-world setting: patterns of care and outcome in the Austrian population

Hainfellner, A., Borkovec, M., Seebrecht, L., Neuhauser, M., Roetzer-Pejrimovsky, T., Greutter, L., Surboeck, B., Hager-Seifert, A., Hof, D. G.-V., Urbanic-Purkart, T., et al. (2024) · Journal of Neuro-Oncology · doi:10.1007/s11060-024-04808-x · Cited by 8 · see citing works

Global analysis of iron metabolism‐related genes identifies potential mechanisms of gliomagenesis and reveals novel targets

Zhang, J., Zhao, L., Xuan, S., Liu, Z., Weng, Z., Wang, Y., Dai, K., Gu, A., & Zhao, P. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14386 · Cited by 7 · see citing works

Epigenetic Biomarkers of Disease

Voyias, P. D., Patel, A. J., & Arasaradnam, R. P. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803239-8.00010-7 · Cited by 6 · see citing works

Pharmacoepigenetics: Basic Principles for Personalized Medicine

Majchrzak‐Celińska, A., & Baer‐Dubowska, W. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813939-4.00002-4 · Cited by 5 · see citing works

Relationship between glioblastoma location and O6-methylguanine-DNA methyltransferase promoter methylation percentage

Sansone, G., Lombardi, G., Maccari, M., Gaiola, M., Pini, L., Cerretti, G., Guerriero, A., Volpin, F., Denaro, L., Corbetta, M., et al. (2024) · Brain Communications · doi:10.1093/braincomms/fcae415 · Cited by 3 · see citing works

Brain tumors – other treatment modalities

Peyrl, A., Frischer, J. M., Hainfellner, J. A., Preusser, M., Dieckmann, K. U., & Marosi, C. (2017) · Handbook of clinical neurology · doi:10.1016/b978-0-12-802395-2.00034-1 · Cited by 2 · see citing works

Defining the recommended gray zone in O6-methylguanine-DNA methyltransferase promoter methylation pyrosequencing reporting: A robust, translatable method to implement new EANO guidelines

Taylor, P., Cruickshank, G., Wildman, J., Doyle, G., Whittaker, E., Walker, S., McKeeve, C., Faulkner, C., Yarram-Smith, L., White, P., et al. (2025) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaf061 · Cited by 1 · see citing works

Methylation of MGMT promoter as a prognostic marker of glioblastoma

Botezatu, I. V., Kondratova, V. N., Строганова, А. М., Dranko, S. L., Насхлеташвили, Д. Р., & Lichtenstein, A. V. (2025) · Advances in molecular oncology · doi:10.17650/2313-805x-2025-12-3-70-77 · Cited by 1 · see citing works

Clinical Validation of a Novel Quantitative Assay for the Detection of MGMT Methylation in Glioblastoma PatientsPreprint

Rosas-Alonso, R., Colmenarejo-Fernández, J., Pernía, O., Rodríguez‐Antolín, C., Esteban, I., Ghanem, I., Sánchez-Cabrero, D., Losantos-García, I., de Castro, J., Martínez-Marín, V., et al. (2020) · Preprints.org · doi:10.20944/preprints202008.0096.v1 · Cited by 1 · see citing works

Current Standards and Emerging Approaches in Glioblastoma

Reardon, D. A. (2017) · American Journal of Hematology / Oncology®

Epigenetic biomarkers of disease

Chaves, P., Onieva, J. L., & Barragán, I. (2021) · Medical Epigenetics · doi:10.1016/b978-0-12-823928-5.00037-2

Methods for detection of DNA methylation in transposable elements

Kvaratskhelia, E., Chikovani, I., Surmava, S., Tkemaladze, T., & Abzianidze, E. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-26759-8.00031-x

Additional file 1 of Clinical validation of a novel quantitative assay for the detection of MGMT methylation in glioblastoma patients

Rosas-Alonso, R., Colmenarejo-Fernández, J., Pernía, O., Rodríguez‐Antolín, C., Esteban, I., Ghanem, I., Sánchez-Cabrero, D., Losantos-Garcia, I., Palacios-Zambrano, S., Moreno-Bueno, G., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14189741

Additional file 5 of The number of methylated CpG sites within the MGMT promoter region linearly correlates with outcome in glioblastoma receiving alkylating agents

Siller, S., Lauseker, M., Karschnia, P., Niyazi, M., Eigenbrod, S., Giese, A., & Tonn, J.-C. (2021) · Figshare · doi:10.6084/m9.figshare.14167954

Additional file 6 of The number of methylated CpG sites within the MGMT promoter region linearly correlates with outcome in glioblastoma receiving alkylating agents

Siller, S., Lauseker, M., Karschnia, P., Niyazi, M., Eigenbrod, S., Giese, A., & Tonn, J.-C. (2021) · Figshare · doi:10.6084/m9.figshare.14167957

Additional file 2 of Clinical validation of a novel quantitative assay for the detection of MGMT methylation in glioblastoma patients

Rosas-Alonso, R., Colmenarejo-Fernández, J., Pernía, O., Rodríguez‐Antolín, C., Esteban, I., Ghanem, I., Sánchez-Cabrero, D., Losantos-Garcia, I., Palacios-Zambrano, S., Moreno-Bueno, G., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14189744

Additional file 3 of Clinical validation of a novel quantitative assay for the detection of MGMT methylation in glioblastoma patients

Rosas-Alonso, R., Colmenarejo-Fernández, J., Pernía, O., Rodríguez‐Antolín, C., Esteban, I., Ghanem, I., Sanchez-Cabrero, D., Losantos-Garcia, I., Palacios-Zambrano, S., Moreno-Bueno, G., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14189747

Cholesteryl Ester as a Prognostic Biomarker In IDH-wildtype GlioblastomaPreprint

wang, N., Wang, J., Liu, J., Zou, J., Yang, B., Wang, P., Ji, N., & Yue, S. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.05.722825

Quantitative DNA melting analysis with hybridization probes (qDMA-HP) as a novel approach to assess MGMT promoter methylation in malignant glioma

Botezatu, I. V., Kondratova, V. N., Строганова, А. М., Prokopev, I. G., Khabarova, A. I., Халафян, Д. А., Bekyashev, A. К., Насхлеташвили, Д. Р., & Lichtenstein, A. V. (2026) · Journal of Neuro-Oncology · doi:10.1007/s11060-026-05648-7

Clinical diagnostic utility of MGMT promoter methylation

Lehmann, U. (2026) · Epigenomics · doi:10.1080/17501911.2026.2688974

Clinical Neuropathology practice news 1-2014: Pyrosequencing meets clinical and analytical performance criteria for routine testing of MGMT promoter methylation status in glioblastoma

Preusser, M., Berghoff, A. S., Manzl, C., Filipits, M., Weinhäusel, A., Pulverer, W., Dieckmann, K. U., Widhalm, G., Wöehrer, A., Knosp, E., et al. (2013) · Clinical Neuropathology · doi:10.5414/np300730 · Cited by 54 · see citing works

Assessing MGMT methylation status and its current impact on treatment in glioblastoma

Berghoff, A. S., Hainfellner, J. A., Marosi, C., & Preusser, M. (2015) · CNS Oncology · doi:10.2217/cns.14.50 · Cited by 33 · see citing works

Detection of MGMT promoter methylation in glioblastoma using pyrosequencing.

Xie, H., Tubbs, R., & Yang, B. (2015) · PubMed · Cited by 40 · see citing works

Outcome-based determination of optimal pyrosequencing assay for MGMT methylation detection in glioblastoma patients

Quillien, V., Lavenu, A., Sanson, M., Legrain, M., Dubus, P. R., Karayan, L., Mosser, J., Ichimura, K., & Figarella-Branger, D. F. (2014) · Journal of Neuro-Oncology · doi:10.1007/s11060-013-1332-y · Cited by 74 · see citing works

MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges

Mansouri, A., Hachem, L. D., Mansouri, S., Nassiri, F., Laperrière, N., Xia, D., Lindeman, N. I., Wen, P. Y., Chakravarti, A., Mehta, M. P., et al. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy132 · Cited by 343 · see citing works